ComplianceOnline

FDA Draft Guidance on Referencing Approved Drugs in ANDA Submissions

  • By: Staff Editor
  • Date: February 21, 2017
  • Source: https://www.fda.gov
Webinar All Access Pass Subscription Abstract:

FDA Draft Guidance on Referencing Approved Drugs in ANDA Submissions

The process for obtaining approval to market a generic drug varies from the process of gaining authorization to market a novel drug under new drug application. The Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD &C) authorizes an applicant to submit FDA an abbreviated new drug application (ANDA) to seek approval for marketing of the generic drugs.

The FDA has recently issued a draft guidance that clarifies these generic drug manufacturers on how to define and use several terms in ANDA submissions.

Bookmark and Share

Trending Compliance Trainings

Trial Master File and Clinical Data Management Regulated by FDA
By - Carolyn Troiano
On Demand Access Anytime
Good Documentation Practice and Record Keeping Regulations (FDA & EMA)
By - Dr. Afsaneh Motamed Khorasani
On Demand Access Anytime
GAMP Data Integrity 21 CFR Part 11 Training Course
By - Kelly Thomas
On Demand Access Anytime
NEW Reclamation Process - Fed Gov't Payments
By - Donna K Olheiser
On Demand Access Anytime
Understanding and Preparing for FDA Pharmaceutical Inspections
By - Michael Ferrante
On Demand Access Anytime
How to conduct an effective BSA Audit
By - Justin Muscolino
On Demand Access Anytime
Installation and Qualification of the Packaging Lines
By - John E Lincoln
On Demand Access Anytime
Best Sellers
You Recently Viewed
    Loading